- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Amivantamab; Lazertinib – March 2025
Amivantamab; Solution concentrate for I.V. infusion 350 mg in 7 mL; Rybrevant®; Lazertinib, Tablet 80 mg (as mesylate monohydrate), Tablet 240 mg (as mesylate monohydrate); Lazcluze®
Last updated
12 March 2025